Home  |  Contact

UniProtKB/Swiss-Prot P16278: Variant p.Gly438Glu

Beta-galactosidase
Gene: GLB1
Variant information

Variant position:  438
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Glycine (G) to Glutamate (E) at position 438 (G438E, p.Gly438Glu).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from glycine (G) to medium size and acidic (E)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In GM1G3 and MPS4B; mild form; 5.7% of wild-type galactosidase activity.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  438
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  677
The length of the canonical sequence.

Location on the sequence:   YRTTLPQDCSNPAPLSSPLN  G VHDRAYVAVDGIPQGVLERN
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         YRTTLPQDCSNPAPL-SSPLNGVHDRAYVAVDGIPQGVLERN

                              YRTTLPQDCSDPTPL-SSPLSGVHDRAYVSVDGVPQGVMER

Mouse                         YRTTLPQDCSNPKPIFSSPFNGVRDRAYVSVDGVPQGILDR

Bovine                        YRTMLPEDCSDPTPL-SSPLSGVHDRAYVSVNGVAQGILER

Cat                           YRTTLPQDCSNPTPL-SSPLNGVRDRAYVAVDGVPQGVLER

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 29 – 677 Beta-galactosidase


Literature citations

Novel mutations (Asn 484 Lys, Thr 500 Ala, Gly 438 Glu) in Morquio B disease.
Bagshaw R.D.; Zhang S.; Hinek A.; Skomorowski M.-A.; Whelan D.; Clarke J.T.R.; Callahan J.W.;
Biochim. Biophys. Acta 1588:247-253(2002)
Cited for: VARIANTS MPS4B GLU-438; LYS-484 AND ALA-500;

Dystonia and parkinsonism in GM1 type 3 gangliosidosis.
Roze E.; Paschke E.; Lopez N.; Eck T.; Yoshida K.; Maurel-Ollivier A.; Doummar D.; Caillaud C.; Galanaud D.; Billette de Villemeur T.; Vidailhet M.; Roubergue A.;
Mov. Disord. 20:1366-1369(2005)
Cited for: VARIANTS GM1G3 HIS-49; GLU-73; CYS-148 AND GLU-438;

GM1 gangliosidosis and Morquio B disease: expression analysis of missense mutations affecting the catalytic site of acid beta-galactosidase.
Hofer D.; Paul K.; Fantur K.; Beck M.; Buerger F.; Caillaud C.; Fumic K.; Ledvinova J.; Lugowska A.; Michelakakis H.; Radeva B.; Ramaswami U.; Plecko B.; Paschke E.;
Hum. Mutat. 30:1214-1221(2009)
Cited for: VARIANTS GM1G1 HIS-59; THR-132; ARG-184; ASP-190; CYS-201; HIS-201; MET-239; HIS-255; ILE-329; GLU-332; ASN-346; GLN-442 AND SER-597; VARIANTS GM1G2 GLN-68; ARG-155 AND HIS-333; VARIANTS GM1G3 MET-82; ASP-270 AND GLU-438; VARIANTS MPS4B PHE-149; TYR-198; LEU-273; ALA-397; PRO-408 AND ALA-500; CHARACTERIZATION OF VARIANTS GM1G1 THR-132; ARG-184; ASP-190; CYS-201; HIS-201; HIS-255; ILE-329; GLU-332 AND SER-597; CHARACTERIZATION OF VARIANTS GM1G2 GLN-68; ARG-155 AND HIS-333; CHARACTERIZATION OF VARIANTS GM1G3 ASP-270 AND GLU-438; CHARACTERIZATION OF VARIANTS MPS4B PHE-149; TYR-198; LEU-273; ALA-397; PRO-408 AND ALA-500; CATALYTIC ACTIVITY; FUNCTION;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.